AddLife AB (publ) (ALIF_B) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and warm welcome to the AdLife third quarter report. As usual, we will take you through the numbers and description of what has happened in the company during the quarter. Then we will open up for a Q&A session. And after that, as usual, we encourage you to stay on for a few more minutes to see an interesting video from one of our companies. This time around is from Health Care 21 Ireland, a very important piece of the puzzle as we are growing throughout Europe and an important platform acquisition. So let's get going with the highlights of the third quarter. So the AdLife companies all had a good quarter in the third quarter of 2025. We saw a strong EBITDA improvement in both business areas. We saw a healthy customer demand, currency adjusted growth increased by 7%, 6% organic and a nice addition of 1% from acquisitions. The growth in Labtech was really strong, 9% excluding currency effects, and on the Medtech side, a very healthy demand in spite of the fact that we are updating our product portfolio and we saw a little bit of a weakness in capital sales. So 5% growth in Medtech, a strong quarter. We are driving profitability improvement initiatives in a handful of companies. These are progressing quite well, but there is more work to do and we think there is more potential to improve the performance of some of the companies within the group. We're pleased to note that we have achieved our net debt to EBITDA goal of being below three. We stick to that goal. That's a good target for us, we think. But of course, now that we are below that level, we can increase the acquisition activity. So with that, I hand over to Kristina to take us through a little bit more of the details of the financials. Welcome, Kristina. Thank you, Fredrik. The companie...